Safety of Combination Vaccines with Whole Cell Pertussis Component
https://doi.org/10.31631/2073-3046-2016-15-6-62-69
Abstract
We consider the safety of domestic products combined (DTP, Bubo Kok) containing whole-cell pertussis vaccine. DTP and Bubo Kok safety vaccines meet WHO requirements, EF and more rigid in some cases, the requirements of Russian regulatory documents. Thus, in assessing the safety of specific pertussis vaccine and complete neutralization of diphtheria and tetanus toxins, are administered to laboratory animals much larger doses of test products in comparison with the requirements of the WHO and the EP. In contrast to the WHO and the EP in the domestic requirements have stringent requirements for quantitative content in the non-adsorbed toxoids vaccine. Compared with foreign counterparts, domestic vaccines are significantly less anti-genetic load, that is responsible for their low reactivity, at the same time they possess the desired immunogenic activity.
About the Authors
O. V. Perelygina
Federal State Budgetary Institution «Scientific Center on Expertise of Medicinal Application Products» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
I. A. Alekseeva
Federal State Budgetary Institution «Scientific Center on Expertise of Medicinal Application Products» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Morbidity and Mortality Weekly Report (MMWR). 2012; July 20; 61 (28): 517 – 522.
2. WHO Weekly Epidemiological Record (WER). Pertussis vaccines: WHO position paper. September 2015; 90 (35): 433 – 460.
3. WHO Weekly Epidemiological Record (WER). Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – conclusions and recommendations. 2014; 89 (21): 221 – 236. Available at: http://www.who.int/immunization/sage/meetings/2014/april/SAGE_report_April_2014_RU.pdf?ua=1
4. WHO. Weekly Epidemiological Record (WER). 2004; 79 (29): 269 – 272.
5. WHO. Weekly Epidemiological Record (WER). 2015; 90 (29): 365 – 372.
6. WHO. Weekly Epidemiological Record (WER). 1999; 74 (41): 337 – 340.
7. Zakharova M.S., Tamm O.M., Vorobyov A.I., Märtin Y.K. Pertussis and parapertussis in the Estonian SSR. Tallinn: Valgus; 1983: 82 (in Russian).
8. WHO. Technical Report Series. 1953; 61.
9. WHO. Technical Report Series. 40th report. 1990; 800.
10. WHO. Technical Report Series. Recommendations for whole-cell pertussis vaccine. Annex 6. 2007: 941.
11. WHO. Technical Report Series. 2012; 980: 63.
12. WHO. Manual for Quality Control of Diphtheria, Tetanus and Pertussis Vaccines.2013. Available at: http://apps.who.int/iris/bitstream/10665/80681/1/WHO_IVB_11.11_eng.pdf].
13. European Pharmacopoeia 8th Edition. 2014.
14. Chuprinina RP. Measurement system and quality evaluation of the pertussis component of the DTP vaccine and the problem of standardization of the drug. Avtoreferat dis. ... Dr. med. sciences: 03.00.07. Rostov-on-Don. 1987: 43 (in Russian).
15. Chuprinina RP, Alekseeva IA To a question about the advantages and disadvantages of whole-cell and acellular pertussis vaccines. Epidemiology and Vaccinal Prevention. 2012; 2 (63): 62 – 69 (in Russian).
16. Berman R.F., Pessah I.N., Mouton P.R., Mav D. and Harry J. Low-level neonatal thimerosal exposure: further evaluation of altered neurotoxic potential in SJL mice. Toxicol. Sci. 2008; 101 (2): 294 – 309.
17. Semenov NV. Biochemical components and constants liquids and tissues. Moscow: Medicina. [Medicine]. 1971: 152 (in Russian).
18. The Global Advisory Committee on Vaccine Safety, 20 – 21 June 2002. Available at: http://who.int/vaccine_safety/committee/reports/jun_2002/ru/
19. Сhervonskaya GP, Kravchenko AT, Runova VF.,. Bednyagin VM, Greenberg KN, Mironov LL. The cytotoxic effects of chemical substances contained as impurities in some medical immunobiological preparations. Microbiology Journal. 1988; 12: 85 – 90. (in Russian).
20. Heron J., Golding J. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004; 114 (3): 577 – 583.
21. Hviid A., Stellfeld M., Wohlfahrt J., Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003; 290 (13): 1763 – 1766.
22. Ip P., Wong V., Ho M., Lee J., Wong W. Mercury exposure in children with autistic spectrum disorder: case-control study. J. Child. Neurol. 2004; 19 (6): 431 – 434.
23. Madsen K.M., Lauritsen M.B., Pedersen C.B., Thorson P., Plesner A.M., Andersen P.H. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003; 112 (3; 1): 604 – 606.
24. McCormick M., Bayer R., Berg A. Report of the Institute of Medicine: Immunization safety review – vaccines and autism. Washington, DC: National Academy Press. 2004.
25. Parker S.K., Schwartz B., Todd J., Pickering L.K. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics. 2004; 114 (3): 793 – 804.
26. Stehr-Green P., Tull P., Stellfeld M., Mortenson P.B., Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am. J. Prev. Med. 2003; 25 (2): 101 – 106.
27. Thompson W.W., Price C., Goodson B., Shay D.K., Benson P., Hinrichsen V.L. et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N. Engl. J, Med. 2007; 357 (13): 1281 – 1292.
28. Verstraeten T., Davis R.L, DeStefano F., Lieu T.A., Rhodes P.H., Black S.B. et al. Safety of thimerosal-containing vaccines: a Two-phased study of computerized health maintenance organization databases. Pediatrics. 2003; 112 (5): 1039 – 1048.
29. Andrews N., Miller E., Grant A., Stowe J., Osborne V., Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics. 2004; 114 (3): 584 – 591.
30. Gruis K.L.,Teener J.W., Blaivas M. Pediatric macrophagic myofasciitis associated with motor delay. Clin. Neuropathol. 2006; 25 (4): 172 – 179.
31. Toxicological profile for aluminium. agency for toxic substances and disease registry, September 2008. Available at: http://www.atsdr.cdc.gov/toxprofiles/tp22.pdf]
32. Keith L.S., Jones D.E., Chou C.H. Aluminum toxicokinetics regarding infant diet andvaccinations. Vaccine. 2002; 20 (3): S13 – 17.
33. Lindblad E.B. Aluminium adjuvant – in retrospect and prospect. Vaccine. 2004; 22 (27 – 28): 3658 – 3668.
34. The Global Advisory Committee on Vaccine Safety 3-4 December 2003 Available at: http://who.int/vaccine_safety/committee/reports/dec_2003/ru/.
35. Additional information about the safety of vaccines. Part 2: Fo-new levels of adverse reactions to vaccines. WHO. Geneva. 2001; WHO/V&B/00.36.
36. Tatochenko VK, Ozeretskovsky NA, Fedorov AM. Immunization 2014 (Reference). Moscow. 2014: 200 (in Russian).
37. Plotkin S., Orenstein W., Offit P. (ed.). Vaccines. Philadelphia; 2008.
38. Griffin M.R., Ray W.A., Livengood J.R., Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N. Engl. J. Med. 1988; 319: 618 – 623.
39. Ray P., Hayward J., Michelson D., Lewis E., Schwalbe J., Black S. et al. Vaccine Safety Datalink Group. Encephalopathy after whole-cell pertussis and measles vaccination. lack of evidence for a causal association in a retrospective case-control study. Pediatr. Infect. Dis. J. 2006; 25 (9): 768 – 773.
40. Tatochenko V.K., Fedorov A.M., Ozeretskovsky N.A. Prevention and monitoring of post-vaccination complications. Moscow. 2004;189 (in Russian).
41. Witt M.A., Arias L., Katz P.H., Truong E.T., Witt D.J. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin. Infect. Dis. 2013; 56: 1248 – 1254.
42. Meeting of the Strategie Advisory Group of Experts on Immunization. Nov. 2012. Available at [http://www.who.int/immunization/sage/meetings/2012/november/en/
43. Alekseeva I.A., Chuprinina R.P., Borisova V.N. Comparative analysis of the safety and effectiveness of domestic and foreign complex vaccines containing whole cell pertussis vaccine. Epidemiologiya i Vakcinoprofilaktika. [Epidemiology and Vaccinal Prevention]. 2012; 3 (64): 48 – 54 (in Russian).
44. Chuprinina R.P., Perelygina O.V., Alekseeva I.A., Ozeretskovsky N.A. Comparative characteristics of domestic and foreign vaccines to prevent whooping cough, diphtheria and tetanus. BIOpreparati. [BIOpreparations]. 2006; 4 (24): 27 – 30 (in Russian).
Review
For citations:
Perelygina O.V., Alekseeva I.A. Safety of Combination Vaccines with Whole Cell Pertussis Component. Epidemiology and Vaccinal Prevention. 2016;15(6):62-69. (In Russ.) https://doi.org/10.31631/2073-3046-2016-15-6-62-69
Views:
913
Email this article 